Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

NCT01234402 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

153

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: Ramucirumab DP
BIOLOGICAL: IMC-18F1
DRUG: Capecitabine

Sponsor

Eli Lilly and Company